Drug Trial Radar · NCT05987332
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
Last checked: Nov 20, 2026Latest source record: Feb 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
420
Planned (sponsor's estimate)
Start
Oct 31, 2023
Primary completion
Jan 15, 2027
Study completion Jan 15, 2028
Sponsor
- Lead sponsor
- IDEAYA BiosciencesIndustry
- Sponsor type
- Industry
- First posted
- Aug 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).
Conditions
- Metastatic Uveal Melanoma
Interventions
IDE196Drug
Dosed orally, twice daily
CrizotinibDrug
Dosed orally, twice daily
PembrolizumabDrug
IV administration every 3 weeks
IpilimumabDrug
IV administration every 3 weeks for 4 Cycles
NivolumabDrug
IV administration every 3 Weeks for 4 Cycles, thereafter every 4 Weeks maintenance
DacarbazineDrug
IV administration every 3 Weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2a: To determine the optimal dose of IDE196 + Crizotinib combination for Phase 2B and Phase 3 by evaluating the following:Time frame: Approximately 5 months
- Phase 2 Progression-Free Survival (PFS)Time frame: Approximately 2 years
- Phase 3 Overall Survival (OS) of IDE196 + Crizotinib compared to investigator's choice of treatment.Time frame: Approximately 4 years
Locations
68 sites in 13 countries. Site status is shown where the registry gives one.
Honor Health
Scottsdale, Arizona
Moores Cancer Center
La Jolla, California
UCLA Medical Center
Los Angeles, California
The Angeles Clinic and Research Institute
Los Angeles, California
California Pacific Medical Center (CPMC)
San Francisco, California
University of California San Francisco
San Francisco, California
University of Colorado Cancer Center
Aurora, Colorado
SCRI at HealthONE
Denver, Colorado
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida
Moffitt Cancer Center
Tampa, Florida
Northside Hospital Atlanta
Atlanta, Georgia
University of Iowa
Iowa City, Iowa
Massachusetts General Hospital
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
The Cancer and Hematology Centers
Grand Rapids, Michigan
Minnesota Oncology Hematology, P.A.
Burnsville, Minnesota
Mayo Clinic
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
Roswell Park Cancer Institute
Buffalo, New York
Northwell Health
Manhasset, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Duke University Health System
Durham, North Carolina
University of Cincinnati
Cincinnati, Ohio
The Cleveland Clinic Foundation
Cleveland, Ohio
Thomas Jefferson University
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
SCRI Oncology Partners
Nashville, Tennessee
Texas Oncology- DFW
Dallas, Texas
UT Southwestern Medical Center
Dallas, Texas
Houston Methodist Cancer Center
Houston, Texas
MD Anderson Cancer Center
Houston, Texas
Queen Elizabeth Hospital
Adelaide, Australia
Westmead Hospital
Sydney, New South Wales, Australia
Princess Alexander Hospital
Brisbane, Queensland, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Alfred Health
Melbourne, Victoria, Australia
Sir Charles Gairdner Hospital
Perth, Washington, Australia
Cliniques Universitaires Saint Luc
Brussels, Belgium
Algemene Medische Oncologie UZ
Leuven, Belgium
Cross Cancer Institute, University of Alberta
Edmonton, Alberta, Canada
Showing 40 of 68 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.